Dr. Fairman has over 25 years of biotech experience, leading research that has delivered clinical candidates, vaccines, and immunotherapeutics. He co-founded Vaxcyte in 2013 and assisted in over $4 billion if fundraising and has overseen the pre-clinical and clinical development of their lead pneumococcal conjugate vaccine into Phase III human clinical studies. Prior to Vaxcyte he founded and served as VP of Research at Juvaris BioTherapeutics, where he advanced an immunotherapeutic and vaccine adjuvant platform, leading to the launch of Zelnate® and Victrio® by Bayer HealthCare. He secured major NIH and NCI grants, driving preclinical and clinical programs. Previously, he was Director of Pharmacogenomics at Clingenix and a Senior Scientist at Valentis. Jeff holds a PhD in Chemistry and completed postdoctoral training in leukemia genetics at MD Anderson Cancer Center.